A proof-of-concept phase II trial (NCT02474186) enrolling 41 patients with different metastatic solid tumours found that adding GM-CSF to SBRT could induce abscopal response in 11 (26.8%) patients, including 4 patients with advanced NSCLC [26]. This evidence concerns the gene CSF2 and non-small cell lung carcinoma.